BALPHARMA NSE filing

Bal Pharma sets 18 September 2025 as record date for FY25 dividend, pending AGM approval

The RealCase readMedium impact Positive

Why it matters

The setting of a record date is important for shareholders as it determines eligibility for the dividend. While the dividend amount is not specified, the announcement of the record date is a key step in the dividend distribution process.

The market read

The announcement of a record date for dividend payment indicates a forthcoming distribution of profits to shareholders, which is generally a positive event for investors.

* Bal Pharma Limited's Board of Directors, in their meeting held on 11 August 2025, has fixed 18 September 2025 as the record date for the payment of dividend. * This dividend is for the financial year ended 31 March 2025. * The dividend payment is subject to the approval of the shareholders of the Company at the 38th Annual General Meeting (AGM), which is convened to be held on 25 September 2025.

Filing to action

What to do with a filing like this

Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.

View original filing